

## **2016-2017 ASHI Board Candidates**

### **President-elect**



#### **John L. Schmitz, PhD, D(ABMLI, ABHI)**

Dr. Schmitz is Professor of Pathology and Laboratory Medicine in the School of Medicine at UNC Chapel Hill and Director of the Histocompatibility and Flow Cytometry Laboratories at UNC Hospitals. He received his PhD in Microbiology/Immunology from the University of Wisconsin-Madison and completed a post-doctoral fellowship in Medical Laboratory Immunology at UNC Hospitals where he also completed his training in Clinical Histocompatibility testing. He maintains board certification with American Board of Histocompatibility and Immunogenetics and the American Board of Medical Laboratory.

Dr. Schmitz participates in teaching Medical Students, Pathology Residents and Clinical Fellows at UNC Hospitals and directs the UNC Hospitals Medical

Laboratory Immunology Fellowship Training Program. His histocompatibility experience contributes to research activities in transplantation, autoimmune disease and HIV. Dr. Schmitz is actively involved in ASHI having contributed to several committees including Directors Training Review and Credentialing, Directors Affairs, Program Planning and Bylaws. He is a past ARB Program Director and currently serves on the ASHI Board of Directors.

### **Secretary**



#### **John H. Crawford Jr., BS, CHS**

John Crawford has been in the field of histocompatibility since the summer of 1977, starting as a research tech at Duke University, a Med Tech at VA Medical Center in Durham, supervisor at Howard University and has continued in the field through his current position as supervisor of the Histocompatibility Laboratory at UNC Hospitals. He has always found this to be an exciting and rewarding field. He had the opportunity to serve as an ASHI inspector and had the privilege of serving as a Commissioner on the Accreditation Review Board. John has seen many changes in the field and looks forward to new challenges.

## **Board Member, Doctoral Candidates (choose two)**



### **Myra Coppage, PhD, HCLD (ABB)**

Myra Coppage has worked in histocompatibility and immunogenetics for nearly 30 years, starting as a technologist at the University of Texas Medical Branch in Galveston. She moved to Rochester, NY in 1990's as the supervisor of the tissue typing lab supporting a new transplant program. In the late 1990's she decided to go back to graduate school and was awarded her doctoral degree in 2006. Her lab now supports multiple solid organ programs and both related and unrelated stem cell programs. Myra's academic focus is primarily HLA alloantibody and transplant outcomes. Since 2006 she has been a member of the ASHI Accreditation Review Board and is the 2016 program director. She enjoys the ARB because it allows for interaction with colleagues and helping them maintain the high standards for which ASHI labs are known. Oh.....and she is having her hip replaced in June so will be in a much better mood by the time of the meeting in St. Louis.



### **Carolyn Katovich Hurley, PhD, D(ABHI)**

Carolyn Hurley is a tenured professor in Oncology at Georgetown University, Washington. She joined ASHI in 1985, served as councilor at large and on various committees in 1990s and lectured in regional workshops. She is on the NMDP Histocompatibility Advisory Group since 1992, and is now chair. Dr. Hurley has been in WMDA since 1996 and has coordinated development of standards and accreditation process for international donor exchange. She has been an AFDT/SEOPF specialists course lecturer since 1990; developing web-based training for search coordinators. Immunogenetics research on impact of diversity on structure/function of immune response molecules. Dr. Hurley directs clinical

laboratory typing of registry volunteers using novel DNA typing strategy (Sanger+SSOP) and NGS to examine HLA diversity within well matched donor-recipient pairs.



### **Annette M. Jackson, PhD, D(ABHI)**

Annette Jackson is an Associate Professor in the Department of Medicine and Co-Director of the Immunogenetics Laboratory at Johns Hopkins University. Dr. Jackson began her career in histocompatibility as a technologist in the HLA laboratory at the University of Minnesota. She received her PhD in Immunology from Duke University, investigating the role of epigenetics in controlling T cell receptor VDJ gene rearrangement and allelic exclusion. Dr. Jackson was recruited to Johns Hopkins as an Assistant Professor and obtained board certification as a Laboratory Director by the American Board of Histocompatibility and Immunogenetics.

Dr. Jackson has extensive experience in molecular biology, cellular and serologic assays, and her current research is focused on the role of non-HLA antibodies in kidney allograft injury. She has published on various transplantation topics including epigenetics, HLA incompatible transplantation, and kidney paired donation. Annette became a member of American Society for Histocompatibility and Immunogenetics (ASHI) in 1998 serving as an HLA Laboratory Inspector and has gone on to serve on the National Program Planning Committee, Co-Chair of the Abstract Committee, Histocompatibility Diplomat Certification Exam Committee, and faculty for the ASHI Regional Education Meetings. She currently serves on the AST Transplant Diagnostic COP executive committee and is a Member of the Histocompatibility Banff Working Group. She is also a member of American Association of Immunologists, The Transplantation Society, and the American Society of Transplantation. Dr. Jackson has received research funding from the National Science Foundation and the National Kidney Foundation of Maryland. She is an active speaker and has lectured at the Didactic and Practical Course on Immunogenetics in Mexico City, the AFDT Histocompatibility Specialist Course, Georgetown Teleconference

Series, and in plenary sessions for ASHI, the Federation of Clinical Immunology Societies (FOCIS), American Transplant Congress, and the World Transplant Congress.

Dr. Jackson has been nominated for a position on the ASHI Board of Directors. Her tenure in the field of histocompatibility and immunogenetics beginning as a bench technologist, then research scientist, and finally as a HLA Director will serve her well. She has experience working in complex solid organ and hematopoietic stem cell transplant programs, including a large desensitization program and paired kidney donation program. Annette has also participated in multiple clinical trials to investigate new transplant protocols and therapeutics. Her experience and perspective will allow for unique contributions to the membership of ASHI and the projects and objectives of the ASHI organization going forward.



### **Andrés Jaramillo, PhD, HCLD/CC(ABB)**

Dr. Andrés Jaramillo is the Associate Director of the Histocompatibility Laboratory at the Mayo Clinic in Arizona. He received his PhD from the University of Louisville in 1991. He did his postdoctoral studies in the Banting and Best Department of Medical Research at the University of Toronto and in the Department of Surgery at Washington University in St. Louis. He has been the recipient of several prestigious awards such as a Fulbright Scholarship, Charles H. Best and a Canadian Diabetes Association Fellowships, and an ASHI Scholar Award. He has published more than 200 journal articles, book chapters, and abstracts. He has been an active ASHI member since 1997.

## **International Board Member, Doctoral (choose one)**



### **Heather Dunckley, PhD**


Dr. Dunckley has worked in histocompatibility testing for more than 25 years, starting as a scientist in the Tissue Typing Laboratory in Sydney, Australia, where she trained and became the ASHI Director. During this time, she served as an ASHI Lab Inspector and was a member of the ASHI International Committee. Dr. Dunckley has been a council member and President of ASEATTA and convened the 2004 ASEATTA annual meeting. She also served on several transplant advisory committees in Australia. Dr. Dunckley is ASHI Director of the New Zealand Tissue Typing Laboratory and will continue to serve ASHI as a Lab Inspector.



### **Robert Liwski, MD, PhD**

Dr. Robert Liwski obtained his PhD in Transplantation Immunology in 1999, his MD degree in 2003 and completed his fellowship training in Hematological Pathology in 2006 all at Dalhousie University, Halifax, Canada. He joined ASHI in 2010 and completed ASHI Director training in 2012. He has been the Medical Director of the HLA Laboratory at the Queen Elizabeth II Hospital in Halifax since 2009. He is also a staff Hematopathologist at that institution. In addition, Dr. Liwski is Professor of Pathology and Microbiology & Immunology at Dalhousie University. He was recently appointed as the Medical and Scientific Director of the HLA Laboratory at the Canadian Blood Services Head Office in Ottawa. Dr. Liwski is also the Chair of the Canadian HLA Laboratory Proficiency Testing Committee and a consultant to the Brazilian Histocompatibility Association (ABH) Proficiency Testing Committee. Dr. Liwski's research interests include transplantation immunology, ischemia reperfusion injury and optimization of diagnostic testing in transplantation. Dr. Liwski has developed several optimized testing protocols including the Halifax/Halifaster FCXM and the Rapid Optimized SAB (ROB)

assay. He was awarded the Canadian Association of Pathologists Junior Scientist Award for his research investigating the role of activated Protein Kinase c in prevention of ischemia reperfusion injury and cancer metastasis. Dr. Liwski has been an active member of the histocompatibility community, contributing articles to the ASHI Quarterly and teaching topics in histocompatibility at several venues including ASHI Annual Meetings and Regional Workshops, the Georgetown University Lecture Series, the AFDT Histocompatibility Specialist Course, and the Brazilian Histocompatibility Association (ABH) Workshops. Within ASHI, Dr. Liwski is or has been a member of the Proficiency Testing Committee (2014 - 2016), the Scientific Affairs Committee (2015), the ASHI Annual Meeting Planning Committee (2015) and an abstract reviewer (since 2012). Dr. Liwski thanks the ASHI Nominations Committee for nominating him to serve on the ASHI Board of Directors.



### **Derek Middleton, DSc, PhD, FRCPath**

Derek Middleton, DSc, PhD, FRCPath, is the Consultant Clinical Scientist and Head of Transplantation Immunology at the Royal Liverpool University Hospital. He previously held the same position at N.Ireland H&I Lab. Dr. Middleton was Visiting Professor at the School of Biomedical Science, University of Ulster and Honorary Professor University of Liverpool.

Dr. Middleton received ASHI's Distinguished Scientist Award in 2013. He was Chair of ASHI's International Affairs Committee from 1995-99 and again from 2012-15. He was also a member of ASHI's Scientific Affairs Committee from 2007-15. Dr. Middleton has attended every ASHI meeting bar 2 since 1987, moderating plenary, abstract and teaching sessions. He has performed accreditation services for ASHI as an inspector and N.Ireland Lab only UK lab to hold ASHI accreditation (1994 to 2009). He is an enthusiast for the global H & I community and has gained a lot from his association with ASHI and wants to give something back. Dr. Middleton received the UK NHS Healthcare Science Award -Excellence in Research in 2012. He is the author of 350 scientific publications, has held 30 grants and supervised over 50 local students and also many foreign students, some as part of their PhD. Dr. Middleton is the originator and webmaster of [www.allelefrequencies.net](http://www.allelefrequencies.net). He's the Joint-President of 17<sup>th</sup> International Histocompatibility Workshop, 2017 and Co-Chair/Organizer of 16<sup>th</sup> Workshop, Liverpool, 2012. Chairman and Co-Founder British Society for H&I, (BSHI) 1993-96. Dr. Middleton initiated the N. Ireland BMDR, directing scientific aspect and Chair of Fund Raising Committee. He is the Joint Editor for the International Journal of Immunogenetics, section editor of Human Immunology and a member of Editorial Board of Tissue Antigens. He's been invited to lecture in more than 30 countries. Dr. Middleton has served as Treasurer of British Transplantation Society and held membership of several UK Transplant Committees. He has provided on-call advisory service single handed for 45 years. Dr. Middleton has developed molecular typing methods in Belfast since 1982 and has helped labs in other countries to establish these techniques.